Outset Medical raises $76.5m Series C to support Tablo all-in-1 hemodialysis system

Outset Medical said today it raised $76.5 million in a Series C equity funding round to support its Tablo hemodialysis system. The Tablo system is an all-in-one dialysis machine which handles both water purification and dialysate production and is designed to be used in a variety of settings, CEO Leslie Trigg told MassDevice.com. The system is equipped with a touch screen interface and designed to be used by even the most basic user, Trigg said, something that sets it apart from other hemodialysis systems on the market. “We designed it so that it’s acceptable for the average patient user to set up and manage their own treatment. That’s number 1. We do that not only through a touch screen, but more importantly through a lot of sensor based automation, removing all the manual steps of dialysis, so it’s much more like a self-driving car and a lot less like a conventional dialysis machine. That is what we were aiming for,” Trigg said in an interview. Funding from the round will allow the company to commercialize the Tablo across 4 markets in the US, and to begin exploring markets outside it, Trigs said. In the US, the company has 4 addressable markets, including existing dialysis clinics, new dialysis clinics, hospitals and skilled nursing facilities, and eventually for home use. In looking outside the US, Trigg said that the company had eyes on China, seeing it as a major market for the all-in-one hemodialysis machine. “This also allows us to dip our toe...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Blood Management Business/Financial News Outset Medical Source Type: news